- Zacks•8 days ago
Genmab (GNMSF) is seeing solid earnings estimate revision and is well-positioned from a Zacks Industry Rank perspective.
- Zacks•11 days ago
Genmab (GNMSF) sees solid estimate revisions, but seems to be overlooked by the investors.
- MarketWatch•14 days ago
European stocks closed higher Friday, a move that solidified a rise for blue-chip equities for a third consecutive week.
GEN.CO : Summary for Genmab A/S - Yahoo Finance
Genmab A/S (GEN.CO)
Copenhagen - Copenhagen Delayed Price. Currency in DKK
Add to watchlist
|Day's Range||1,169.00 - 1,180.00|
|52 Week Range||605.50 - 1,338.00|
|PE Ratio (TTM)||98.02|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|